Table 3 Summary of efficacy in QuANTUM-R and ADMIRAL studies
Parameter | QuANTUM-R [46] | ADMIRAL [31] | ||
|---|---|---|---|---|
Quizartinib (n = 245) | Salvage chemotherapy (n = 122) | Gilteritinib (n = 247) | Salvage chemotherapy (n = 124) | |
Best response, n (%) | ||||
CRc | 118 (48.2) | 33 (27.0) | 134 (54.3) | 27 (21.8) |
CR | 10 (4.1) | 1 (0.8) | 52 (21.1) | 13 (10.5) |
CRi | 99 (40.4) | 32 (26.2) | 63 (25.5) | 14 (11.3) |
CRh | NA | NA | 32 (13.0) | 6 (4.8) |
Median OS, months (95% CI) | 6.2 (5.3–7.2) | 4.7 (4.0–5.5) | 9.3 (7.7–10.7) | 5.6 (4.7–7.3) |
OS, HR (95% CI) | 0.76 (0.58–0.98); one-sided p = 0.02 | 0.64 (0.49–0.83); two-sided p < 0.001 | ||
1-year OS rate, % | 27 | 20 | 37 | 17 |
Eligibility | Refractory or relapsed (duration of first CRc of ≤ 6 months) to anthracycline-containing or mitoxantrone-containing chemotherapy FLT3-ITD | Refractory or relapsed to anthracycline-containing chemotherapy or an alternative therapy appropriate to induce remission FLT3-ITD or FLT3-TKD | ||